Carbachol and Brimonidine
Brand names: Yuvezzi · Active ingredient: Carbachol, Brimonidine Tartrate
In short: YUVEZZI™ is indicated for the treatment of presbyopia in adults.
What is Carbachol and Brimonidine used for?
YUVEZZI™ is indicated for the treatment of presbyopia in adults.
Carbachol and Brimonidine dosage
The recommended dosage of YUVEZZI is one drop in each eye once daily.
Remove contact lenses prior to instillation of YUVEZZI. Wait 10 minutes after dosing before reinserting contact lenses.
If more than one topical ophthalmic medication is being used, the medicines must be administered at least 5 minutes apart.
One single-dose vial can be used to dose both eyes. Discard the open single-dose vial and any remaining contents immediately after use.
How to take Carbachol and Brimonidine — instructions & advice from the label
Night Driving
Advise patients that they may experience temporary dim or dark vision. Advise patients to exercise caution with night driving and when hazardous activities are undertaken in poor illumination
.
Blurred Vision
Temporary problems when changing focus between near objects and distant objects may occur. Advise patients not to drive or use machinery if vision is not clear
.
When to Seek Physician Advice
Advise patients to seek immediate medical care with sudden onset of flashes of lights, floaters, or vision loss
.
Contact Lens Wear
Advise patients to remove contact lenses prior to the instillation of YUVEZZI. Wait 10 minutes after dosing before reinserting contact lenses
.
Potential for Eye Injury or Contamination of the Product
Advise patients to avoid touching the tip of the single-dose vial to the eye, eyelids, or to any other surface to prevent eye injury or contamination
. Advise patients to discard the opened single-dose vial and any remaining contents immediately after use.
Concomitant Topical Ocular Therapy
Advise patients that if more than one topical ophthalmic medication is being used, the medicines must be administered at least 5 minutes apart
.
Warnings & precautions
Do not take this medicine if: YUVEZZI is contraindicated in patients with known hypersensitivity to the active ingredients or to any of the excipients.
Miotics may cause accommodative spasm. Advise patients to not drive or operate machinery if vision is not clear (e.g., blurred vision).
In addition, patients may experience temporary dim or dark vision with miotics. Advise patients to exercise caution in night driving and other hazardous activities in poor illumination.
Rare cases of retinal tear and detachment have been reported with miotics. Individuals with pre-existing retinal disease are at increased risk. Examination of the retina is advised in all patients prior to the initiation of therapy.
Advise patients to seek immediate medical care with sudden onset of flashes of lights, floaters, or vision loss.
Sequelae of ocular inflammation, i.e., adhesions (synechiae) between the iris and the lens, may be exacerbated with miotic use, therefore, YUVEZZI is not recommended to be used when iritis is present.
YUVEZZI may potentiate syndromes associated with vascular insufficiency. YUVEZZI should be used with caution in patients with depression, cerebral or coronary insufficiency, Raynaud's phenomenon, orthostatic hypotension, or thromboangiitis obliterans.
To prevent eye injury or contamination, avoid touching the single-dose vial to the eye, eyelids, or to any other surface.
Carbachol and Brimonidine side effects
The following clinically significant adverse reactions are described elsewhere in labeling:
Hypersensitivity
Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.
YUVEZZI was evaluated in 536 patients with presbyopia in two randomized, double-masked, controlled studies. BRIO™ I (NCT05270863) was a single-dose crossover study in which 178 patients received YUVEZZI. BRIO II (NCT05135286) included 358 patients who received YUVEZZI in the long-term safety portion of the study (up to 12 months duration, including a 6-month open-label extension). Adverse reactions reported in > 5% to 7% of participants were eye pain upon instillation and visual impairment. Adverse reactions reported in > 10% to 16% of participants were eye irritation upon instillation and headache. The majority of adverse events were mild, transient, and self-resolving.
Drug interactions
Because brimonidine tartrate, a component of YUVEZZI, may reduce blood pressure, caution in using drugs such as antihypertensives and/or cardiac glycosides with YUVEZZI is advised.
Although specific drug interaction studies have not been conducted with YUVEZZI, the possibility of an additive or potentiating effect with central nervous system (CNS) depressants (alcohol, opiates, barbiturates, sedatives, or anesthetics) should be considered.
Tricyclic antidepressants have been reported to blunt the hypotensive effect of systemic clonidine. It is not known whether the concurrent use of these agents with YUVEZZI in humans can lead to resulting interference with pupil constriction effects. Caution is advised in patients taking tricyclic antidepressants, which can affect the metabolism and uptake of circulating amines.
Monoamine oxidase (MAO) inhibitors may theoretically interfere with the metabolism of brimonidine tartrate and potentially result in an increased systemic side effect such as hypotension. Caution is advised in patients taking MAO inhibitors which can affect the metabolism and uptake of circulating amines.
About this medicine
YUVEZZI (carbachol and brimonidine tartrate ophthalmic solution) 2.75% / 0.1% is a fixed-dose combination of carbachol, a cholinergic agonist, and brimonidine, an alpha-adrenergic receptor agonist, for topical ophthalmic use. YUVEZZI is formulated as an isotonic, sterile, clear, greenish-yellow ophthalmic solution. YUVEZZI does not contain an anti-microbial preservative.
The chemical name for carbachol is 2-carbamoyloxyethyl(trimethyl)azanium chloride. The molecular weight is 182.648 g/mol and the molecular formula is C
6H
15ClN
2O
2. Its structural formula is:
The chemical name for brimonidine tartrate is 5-bromo-N-(4,5-dihydro-1H-imidazol-2-yl)-6-quinoxalinamine L-tartrate. The molecular weight is 442.226 g/mol and the molecular formula is C
15H
16BrN
5O
6. Its structural formula is:
Each mL of YUVEZZI contains carbachol 2.75% (27.5 mg/mL) and brimonidine tartrate 0.1% (1 mg/mL) as the active ingredients. …
Source: FDA-approved label via DailyMed (U.S. National Library of Medicine), label set ID 68198098-0f33-458f-83b8-eb2a5ec69012. Read the full official label on DailyMed.